Navigation Links
BioLineRx Reports Third Quarter 2013 Financial Results
Date:11/13/2013

ded September 30, 2013 amounted to NIS 11.6 million ($3.3 million), compared with an operating loss of NIS 19.6 million ($5.5 million) for the comparable period in 2012. The Company's operating loss for the nine months ended September 30, 2013 amounted to NIS 52.1 million ($14.7 million), compared with an operating loss of NIS 58.5 million ($16.5 million) for the comparable period in 2012.

The Company's net non-operating expenses amounted to NIS 4.6 million ($1.3 million) for the three months ended September 30, 2013, an increase of NIS 1.4 million ($0.4 million), compared to net non-operating expenses of NIS 3.2 million ($0.9 million) for the three months ended September 30, 2012. Non-operating expenses primarily relate to fair-value adjustments of liabilities on account of the warrants issued in the private and direct placements completed in February 2012 and 2013. Net non-operating income amounted to NIS 9.2 million ($2.6 million) for the nine months ended September 30, 2013, an increase of NIS 6.9 million ($1.9 million), compared to net non-operating income of NIS 2.4 million ($0.7 million) for the comparable 2012 period. Non-operating income for both periods primarily relate to fair-value adjustments of liabilities on account of warrants, as discussed above in the three-month comparison.

Net financial expenses amounted to NIS 1.5 million ($0.4 million) for the three months ended September 30, 2013, a change of NIS 1.6 million ($0.5 million), compared to net financial income of NIS 0.2 million ($0.1 million) for the three months ended September 30, 2012. Net financial income and expenses result primarily from changes in the average exchange rate of the dollar in relation to the NIS during the respective periods, which have a direct effect on net assets denominated in dollars. Net financial expenses amounted to NIS 3.2 million ($0.9 million) for the nine months ended September 30, 2013, a change of NIS 7.5 million ($2.1 million), c
'/>"/>

SOURCE BioLineRx Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
2. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
3. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
5. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
8. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
9. BioLineRx to Present at 15th International Celiac Disease Symposium
10. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
11. BioLineRx Appoints B. J. Bormann to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , Mar. 30, 2015 Research and ... the addition of the "Medical Device Studies: ... This course has been designed specifically for ... required for medical devices and in-vitro diagnostic products. ... and the emphasis on high quality, appropriate clinical ...
(Date:4/1/2015)...  Egalet Corporation (Nasdaq: EGLT ) ("Egalet"), ... developing, manufacturing and marketing innovative pain treatments, today ... million aggregate principal amount of its convertible senior ... placement to qualified institutional buyers pursuant to Rule ... amended (the "Act"). Egalet also granted the initial ...
(Date:4/1/2015)... 1, 2015  Salix Pharmaceuticals, Ltd. ("Salix"), a ... (NYSE: VRX ) (TSX:VRX), today announced that ... aggregate principal amount of its 6.00% Senior Notes ... Notes ") pursuant to two redemptions. On May ... amount of the Notes, and on May 4, ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 7Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 2Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 3
... OMAHA, Neb., March 14, 2011 Transgenomic, Inc. ... announced the completion of an expanded license with the ... at Lower Denaturing temperature PCR) technology. Previously, Transgenomic had ... mitochondrial DNA analysis. The new license expands the technology ...
... OrbusNeich today announced the launch of the ... Stent combines the proven stent design of its ... a delivery system with enhanced crossability and flexible ... Helix stent design, offering conformability and radial strength ...
Cached Medicine Technology:Transgenomic Expands COLD-PCR License 2Transgenomic Expands COLD-PCR License 3Transgenomic Expands COLD-PCR License 4OrbusNeich Announces Availability of Azule™ Cobalt Chromium Stent 2
(Date:4/1/2015)... (PRWEB) April 01, 2015 GrassrootsHealth, ... announcing two continuing medical education (CME) courses about ... help practitioners become more confident in measuring, prescribing, ... After completion of these CME courses, practitioners can ... The CME courses available are “Vitamin D, Sunshine, ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 South Florida’s ... Provisional Certificate of Authority (PCOA) approval from the State ... in the ongoing development of a retirement community that ... health, wellness and spiritual development. , America’s aging population ... meet the housing needs of seniors, according to a ...
(Date:4/1/2015)... FL (PRWEB) April 01, 2015 IQ ... growing health and nutritional supplement companies in the U.S., today ... the testing and quality control standards for its herbal supplements.* ... the supply chain to ensure the accuracy of labeling on ... industry veteran and IQ Formulations CEO Jay Cohen ...
(Date:4/1/2015)... Dr. Rod J. Rohrich , ... the Department of Plastic Surgery at UT Southwestern Medical ... of blindness resulting from the use of facial ... their study, along with ideas for treatment and prevention ... began to see increasing reports of blindness as a ...
(Date:4/1/2015)... Texas (PRWEB) April 01, 2015 Senior ... Best of Home Care Provider of Choice Award by Home ... Choice Award is given to home care providers who ... providers are best-in-class for quality in home care. This recognition ... your satisfaction and will provide you with quality, trustworthy in ...
Breaking Medicine News(10 mins):Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3Health News:Casa Sant’Angelo Receives Approval for New Retirement Living 2Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3Health News:Senior Helpers of Central Texas Awarded Prestigious 2015 Senior Home Care Provider of Choice Award from Home Care Pulse 2
... cancer patients earlier by looking more carefully at CT ... regularly done to determine the extent or stage of ... radiologists at the University College Hospital in Galway, Ireland. ... if left untreated. The study focused on pulmonary embolism ...
... States with undiagnosed diabetes has declined sharply over the past ... than whites to unknowingly have the disease, according to a ... Smith found that in 1999-2002 about 20 percent of American ... disease, in contrast to 25 years ago when about half ...
... a study to be published in the Aug. 21 ... Cardiology, investigators at UT Southwestern Medical Center found that ... increased risk for heart disease. The research evaluates the ... of arterial disease. ,Our study shows that people who ...
... A drug increasingly used to prevent cluster headaches can ... the August 14, 2007, issue of Neurology, the medical ... the drug verapamil for cluster headaches should be closely ... irregular heartbeats. , Cluster headache is a rare, severe ...
... A newly developed DNA vaccine appears safe and may ... of individuals with multiple sclerosis, according to an article ... 2007 print issue of Archives of Neurology, one of ... (MS), the immune system attacks the myelin sheaths that ...
... 13, 2007, Paying out certain types of government aid in ... harmful and often fatal drug binges, according to a new ... Economics that links the monthly arrival of disability checks with ... findings by researchers at the University of California, Santa Cruz ...
Cached Medicine News:Health News:RAND finds cases of undiagnosed diabetes drop sharply 2Health News:RAND finds cases of undiagnosed diabetes drop sharply 3Health News:Waist-to-hip ratio may better predict cardiovascular risk than body mass index 2Health News:Drug for cluster headaches may cause heart problems 2Health News:DNA vaccine against multiple sclerosis appears safe, potentially beneficial 2Health News:Disability payments may spur drug abuse 2
The Sonic WAVE™is the first market-ready Alternative to Ultrasound...
... Profile pHOx series consists of six analyzer models ... care profiles. Measured tests include pH, PCO 2 ... hemoglobin, sodium, potassium, ionized calcium, chloride, glucose, and ... one minute. Its space saving design provides the ...
... The robust, compact Sleepscan Traveler provides the ... can acquire PSG data in the home, ... laboratory. Traveler sleep studies utilize the same ... in-lab studies. Sleepscan Traveler studies take full ...
... Nihon Kohden developed the world's ... that was completely AC powered ... have developed a number of ... Potential/EMG measuring systems, such as ...
Medicine Products: